Production (Stage)
Oruka Therapeutics, Inc.
ORKA
$12.58
$0.393.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -14.02% | 59.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -33.03% | 27.19% | |||
| Operating Income | 33.03% | -27.19% | |||
| Income Before Tax | 37.11% | -16.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 37.11% | -16.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.11% | -16.66% | |||
| EBIT | 33.03% | -27.19% | |||
| EBITDA | 33.04% | -27.14% | |||
| EPS Basic | 26.99% | 62.93% | |||
| Normalized Basic EPS | 32.05% | 61.11% | |||
| EPS Diluted | 26.99% | 62.93% | |||
| Normalized Diluted EPS | 32.05% | 61.11% | |||
| Average Basic Shares Outstanding | -4.97% | 192.14% | |||
| Average Diluted Shares Outstanding | -4.97% | 192.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||